Impact of the amotosalen/UVA process to reduce pathogens in platelet concentrates on transfusion efficiency in cardiac surgery
Abstract
Background: Pathogen reduction treatment (PRT) of platelet concentrates (PC) is one of the most recent advances in improving blood safety and lowering the risk of transfusion-transmitted diseases. The characteristics of PR-treated PC differ slightly from those of untreated PC and may affect transfusion outcomes. We established how effective PRT methods, (INTERCEPT™ Blood System) PC are when transfused to cardiac surgery patients.Materials and methods: This study examined the influence of PRT using amotosalen and UVA light in a population of cardiac surgery patients. We analysed bleeding and platelet drop following cardiopulmonary bypass (CPB) surgery. We selected 73 patients after considering the medical exclusion criteria: 46 patients transfused with untreated platelet concentrate versus 27 patients transfused with PRT-treated platelet concentrate.Results: Data analysis concerns the readout after the first platelet concentrate transfusion. The decrease in patient platelet count between pre-operative and H0 [Intensive Care Unit (ICU) admission], and pre-operative and H6 post-surgery did not differ significantly with or without PRT. The volume of postoperative bleeding after CPB surgery did not differ significantly regardless of whether the patient was transfused with PRT-PC or untreated PC. No difference was documented between the groups in terms of postoperative pulmonary infection rate. Regardless of the use of platelet PRT, among the factors associated with bleeding, only Fg level was independently and significantly associated. A 1mg/L increase in fibrinogen (pre-operative) is associated with a 159mL decrease in bleeding 24hours post-surgery.Discussion: In postoperative cardiac surgery, the use of platelets treated with amotosalen/UVA for pathogen reduction does not appear to affect transfusion effectiveness and postoperative bleeding.
Related
- Supernatants from stored platelet concentrates modulate the inflammatory response in platelet-depleted blood ex vivo
- A ROS-responsive platelet extracellular vesicle biomimetic nanosystem regulates CD36/Fyn-CXCL-NETosis pathway-mediated immune-inflammatory amplification in the treatment of transfusion-related acute lung injury
- Severe allergic transfusion reactions to group B/AB plasma or platelets in group O recipients are linked to α-Gal sensitization
- Long-term exposure to laboratory conditions: can adaptation reshape the biology of pathogens?
- Editorial: Evolution of antimicrobial resistance in intracellular bacterial pathogens: a genomic and historical perspective
BibTeX
@article{bouali2026impact,
title = {{Impact of the amotosalen/UVA process to reduce pathogens in platelet concentrates on transfusion efficiency in cardiac surgery}},
author = {Belkacem Bouali and Ayoub Rezzaoui and Hind Hamzeh-Cognasse and Anne-Claire Duchez and Alexandre Mansour and Cecile Aubron and Zsuzsanna Wolf and Nesrine Tebbeb and Marie-Ange Eyraud and Charles-Antoine Arthaud and Amélie Prier and Patricia Chavarin and Julien Lanoiselée and Kazra Azarnoush and Jerome Morel and Jean Charles Palao and Fabrice Cognasse},
journal = {Transfusion Clinique et Biologique},
year = {2026},
month = sep,
doi = {10.1016/j.tracli.2026.02.005},
url = {https://univ-rennes.hal.science/hal-05653327v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of the amotosalen/UVA process to reduce pathogens in platelet concentrates on transfusion efficiency in cardiac surgery
AU - Belkacem Bouali
AU - Ayoub Rezzaoui
AU - Hind Hamzeh-Cognasse
AU - Anne-Claire Duchez
AU - Alexandre Mansour
AU - Cecile Aubron
AU - Zsuzsanna Wolf
AU - Nesrine Tebbeb
AU - Marie-Ange Eyraud
AU - Charles-Antoine Arthaud
AU - Amélie Prier
AU - Patricia Chavarin
AU - Julien Lanoiselée
AU - Kazra Azarnoush
AU - Jerome Morel
AU - Jean Charles Palao
AU - Fabrice Cognasse
PY - 2026
DA - 2026/09/02
JO - Transfusion Clinique et Biologique
DO - 10.1016/j.tracli.2026.02.005
UR - https://univ-rennes.hal.science/hal-05653327v1
AB - Background: Pathogen reduction treatment (PRT) of platelet concentrates (PC) is one of the most recent advances in improving blood safety and lowering the risk of transfusion-transmitted diseases. The characteristics of PR-treated PC differ slightly from those of untreated PC and may affect transfusion outcomes. We established how effective PRT methods, (INTERCEPT™ Blood System) PC are when transfused to cardiac surgery patients.Materials and methods: This study examined the influence of PRT using amotosalen and UVA light in a population of cardiac surgery patients. We analysed bleeding and platelet drop following cardiopulmonary bypass (CPB) surgery. We selected 73 patients after considering the medical exclusion criteria: 46 patients transfused with untreated platelet concentrate versus 27 patients transfused with PRT-treated platelet concentrate.Results: Data analysis concerns the readout after the first platelet concentrate transfusion. The decrease in patient platelet count between pre-operative and H0 [Intensive Care Unit (ICU) admission], and pre-operative and H6 post-surgery did not differ significantly with or without PRT. The volume of postoperative bleeding after CPB surgery did not differ significantly regardless of whether the patient was transfused with PRT-PC or untreated PC. No difference was documented between the groups in terms of postoperative pulmonary infection rate. Regardless of the use of platelet PRT, among the factors associated with bleeding, only Fg level was independently and significantly associated. A 1mg/L increase in fibrinogen (pre-operative) is associated with a 159mL decrease in bleeding 24hours post-surgery.Discussion: In postoperative cardiac surgery, the use of platelets treated with amotosalen/UVA for pathogen reduction does not appear to affect transfusion effectiveness and postoperative bleeding.
SN - 1246-7820
SN - 1953-8022
ER -